Highlights

• Martin Walton becomes Chief Executive of EDX Medical Group with immediate effect from 17 November 2026.

• Walton brings over 35 years of finance experience and 15 years in life sciences as investor or officer.

• Co-founder Dr Michael Hudson leaves the board but stays on as a consultant focused on international partnerships.

• Founder Professor Sir Christopher Evans takes the role of Deputy Chairman as the board is reshaped.

A finance professional with a long record in life sciences now leads EDX Medical Group (LSE:EDX). Martin Walton has been appointed Chief Executive with immediate effect, part of a wider set of board changes that the company ties to its move into a growth-focused commercial phase.

Martin Walton's background

Walton brings more than 35 years of experience in finance. For 15 of those years, he has worked in life sciences, either as an investor or as an officer of companies in the sector.

His appointment took effect on 17 November 2026. The announcement does not set out details of his remuneration or any share Options attached to the role.

Changes among the founders

Dr Michael Hudson, a co-founder of EDX Medical Group (LSE:EDX), stepped down as a director with effect from the close of Business on 16 November 2026. He is not leaving the business, however: Hudson continues as a consultant and takes the title of Director, International Strategy & Partnerships.

Meanwhile, founder Professor Sir Christopher Evans has been appointed Deputy Chairman. That keeps a founder in a senior board position as the new Chief Executive settles in.

A strengthened board

The Leadership changes follow the recent addition of three independent non-executive directors to the EDX board. Taken together with the new Chief Executive and the Deputy Chairman appointment, the group's governance structure has been substantially refreshed over a short period.

The commercial phase

EDX Medical Group (LSE:EDX) describes the changes as part of its transition into a growth-focused commercial phase. Pairing a Chief Executive with a background in finance and life sciences Investment with founders who remain involved in strategy and partnerships reflects that shift in emphasis.

Understanding the Leadership Changes

The announcement describes several linked changes. Martin Walton has been appointed Chief Executive with effect from 17 November 2026. Dr Michael Hudson, a co-founder, stepped down as a director from the close of business on 16 November 2026 but continues as a consultant with the title of Director, International Strategy & Partnerships. Professor Sir Christopher Evans, also a founder, has been appointed Deputy Chairman. These steps follow the recent addition of three independent non-executive directors.

What the Background Indicates

Walton has more than 35 years of experience in finance, including 15 years in life sciences either as an investor or as an officer of companies in the sector. A background in finance and life sciences investment is relevant to a company describing a transition into a growth-focused commercial phase, since that phase typically involves decisions about funding, partnerships and the commercial rollout of products. The announcement does not set out details of his remuneration or any share options attached to the role, so readers should treat those points as not yet disclosed. Keeping founders in senior positions, as Deputy Chairman and as a consultant with a strategic role, provides continuity of knowledge about the business and its partnerships while the new Chief Executive begins work. Independent non-executive directors are board members who are not part of the executive team and who bring external perspective, challenge and oversight to board discussions. With three recent appointments of that kind, the board's composition has changed noticeably in a short time. For readers following EDX Medical Group, the announcement sets out who holds which role, from when, and how the company describes the purpose of the changes. Further information on strategy and performance is expected through the company's other announcements.

The appointment took effect on 17 November 2026, and the company ties the changes to its transition into a growth-focused commercial phase. Readers following the company can watch for updates on how the new leadership structure develops, including any further board changes or announcements on strategy that the company chooses to make in the coming months.